Molecular signature-assisted drug selection may improve results in rheumatoid arthritis
Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy. “This study reports the second interim analysis of the [Accelerate Information of Molecular Signatures (AIMS)] real-world study evaluating the clinical utility of